Co-Diagnostics, Inc
Financing
SEC filings to 2026-10-05 · every row opens its filingShares on issue
4.88M
on 2026-06-30, from 1.04M on 2024-03-31 10-Q ↗
Earlier counts are adjusted for the 1-for-30 reverse split; each bar's tip shows the count as filed.
a raise that quarter, at its price
$9.7M
Agreement of 2025-12-19. No at-the-market sales statement read from a 10-Q or 10-K. 424B5 ↗
Warrants
16K
Warrants of every class as tagged in the XBRL facts on 2023-12-31. Adjusted for the 1-for-30 reverse split. 10-K ↗
Cash
0.5 quarters
$3.6M on 2026-06-30 ÷ $6.8M a quarter of operating cash used, the average of four quarters. 10-Q ↗
| Date | What | Shares | Price | Gross | Filing |
|---|---|---|---|---|---|
| 2026-07-27 | Public offering | not read | $11.19 | not read | 424B5 ↗ |
| 2025-10-28 | Registered direct offering incl. 0.72M pre-funded | 12,727,272 | $0.55 | $7.0M | 424B5 ↗ |
| 2025-10-20 | Public offering | not read | $0.6388 | not read | 424B5 ↗ |
| 2025-09-17 | Registered direct offering | 9,619,000 | $0.40 | $3.8M | 424B5 ↗ |
Also on file: a 1-for-2 reverse split, 2025-12-29 8-K ↗